Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Michael Frederick Bassetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5012-8596; OpenAlex author ID A5073499506, A5146552068. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2014: 1 trial · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 10

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  3. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Last author DOI 10.1016/j.prro.2025.01.011↗
  4. Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models. Co-author DOI 10.1126/sciadv.adx2984↗
  5. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label… Co-author DOI 10.1016/j.radonc.2023.110064↗
  6. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable… Co-author DOI 10.1016/j.ijrobp.2023.05.023↗
  7. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2020.09.010↗
  8. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  9. Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. Co-author DOI 10.3390/diagnostics11010072↗
  10. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Co-author DOI 10.1002/cam4.2100↗

Trials 1

  1. Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer Principal investigator NCT01918644↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael David Chuong · 5 shared papers, 2021–2026 · strength 0.78
  2. Nataliya Volodymyrivna Uboha · 3 shared papers, 2021–2025 · strength 0.51
  3. Hyun Jee Kim · 3 shared papers, 2023–2025 · strength 0.46
  4. Parag Jitendra Parikh · 4 shared papers, 2019–2024 · strength 0.46
  5. Percy P. Lee · 4 shared papers, 2019–2024 · strength 0.46
  6. Nina Niu Sanford · 2 shared papers, 2025–2026 · strength 0.41
  7. Marsha Reyngold · 2 shared papers, 2025–2026 · strength 0.41
  8. Karyn A. Goodman · 2 shared papers, 2025–2026 · strength 0.41
  9. Amol Kumar Narang · 2 shared papers, 2025–2026 · strength 0.41
  10. Luca Boldrini · 3 shared papers, 2021–2024 · strength 0.38
  11. Lorenzo Placidi · 3 shared papers, 2021–2024 · strength 0.38
  12. Lorraine Portelance · 3 shared papers, 2019–2024 · strength 0.35
  13. Sean M. Ronnekleiv‐Kelly · 2 shared papers, 2021–2025 · strength 0.31
  14. Noelle K. LoConte · 2 shared papers, 2021–2025 · strength 0.31
  15. Daniel Erik Abbott · 2 shared papers, 2021–2025 · strength 0.31
  16. Jacob S. Witt · 2 shared papers, 2021–2025 · strength 0.31
  17. Sharon Marie Weber · 2 shared papers, 2021–2025 · strength 0.31
  18. Bradley A. Erickson · 2 shared papers, 2021–2025 · strength 0.29
  19. William Adrian Hall · 2 shared papers, 2021–2025 · strength 0.29
  20. E.S. Paulson · 2 shared papers, 2021–2025 · strength 0.29
  21. John Ng · 2 shared papers, 2023–2024 · strength 0.27
  22. Kathryn Elizabeth Mittauer · 2 shared papers, 2023–2024 · strength 0.27
  23. Alex T. Price · 2 shared papers, 2023–2024 · strength 0.27
  24. Adam Christopher Mueller · 2 shared papers, 2023–2024 · strength 0.27
  25. Bassem I. Zaki · 2 shared papers, 2023–2024 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.